Omalizumab therapy was linked to improved inflammatory biomarkers and symptom scores after 16 weeks in patients with severe allergic asthma.

Researchers compared the effectiveness of 3 biologics for moderate to severe asthma in an observational study and found superior improvement with dupilumab. Dupilumab was associated with higher ...

More than 60% of participant dietary consumption plans showed no significant difference between omalizumab and multi-food oral immunotherapy success rates after 12 months MILWAUKEE, Feb. 22, 2026 ...

Please provide your email address to receive an email when new articles are posted on . 87.3% of white patients and 92.8% of Black patients had no severe exacerbations with omalizumab. 4% of white ...

JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO ® (omalizumab-igec) as the first and only biosimilar designated ...

Please provide your email address to receive an email when new articles are posted on . In a retrospective analysis, researchers found omalizumab to be an effective treatment in patients with ...

Objectives: To describe allergic asthma and allergic rhinitis pathophysiology and review the pharmacologic, pharmacokinetic, pharmacodynamic, efficacy, and safety data for omalizumab. Methods: MEDLINE ...

This is a case study of a male patient with Fabry disease who presented with severe anaphylaxis following re-initiation of full-strength treatment with intravenous agalsidase beta (Fabrazyme). A ...

Among those who received omalizumab, a 1044 mg dose of 1, 2, and 3 allergenic foods had no adverse effect in 80%, 69%, and 47% of participants, respectively. Omalizumab for 16 weeks increased the ...

Findings showed equivalent efficacy in change from baseline in weekly itch severity score between omalizumab-igec 300mg and Xolair 300mg. The Food and Drug Administration (FDA) has approved Omlyclo ® ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory condition in the U.S., drugmaker Celltrion announced Monday. The ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of omalizumab, having considered evidence on the nature of chronic spontaneous urticaria and the value placed ...